Jan 07, 2021

Molecular subtypes of common pancreatic cancers can be predicted from tumour characteristics

Gene expression analysis of pancreatic ductal adenocarcinoma (PDAC) tumours enables clinicians to stratify patients into molecular subgroups and select treatments that are best suited to each type; however, molecular subtyping remains cost-prohibitive and is not yet part of routine cancer care.

Dec 17, 2020

Study shows Canada Genome Centres primed for COVID-19 host sequencing

Large-scale genome sequencing initiatives frequently rely on datasets provided by different sequencing centres, all of which may employ different laboratory protocols, instruments and analytical methods that may introduce disparities in the data produced. When combining datasets generated at different institutions, how do researchers ensure consistency between datasets?    

Nov 26, 2020

Whole genome and transcriptome sequencing uncovers biomarkers predicting response to immune checkpoint inhibitors

The development of immune checkpoint inhibitors (ICI), a type of cancer therapy that helps the immune system fight tumours, was one of the most significant milestones in cancer treatment in the last decade. While ICI therapy has been used to treat different cancer types, it is not universally effective and relapsed disease occurs. A robust strategy for predicting which patients are likely to respond to ICIs is needed, enabling clinicians to select the best course of treatment for each patient.

Nov 26, 2020

Voicing the Silent Genomes: new documentary features GSC Scientist, Dr. Nadine Caron

The vision of precision medicine is customized health care—preventative measures, disease treatments, practices and products tailored to individuals. Genomics is leading the charge by investigating and cataloguing the chemistry of life using an ever-increasing range of nucleic acid sequencing techniques and powerful computational technologies. But what if the genomic information that is being databased and used to inform modern medical science is not equitable?
Nov 19, 2020

The GSC Welcomes Dr. Laura Evgin

The GSC is pleased to announce the arrival of our newest faculty member, Dr. Laura Evgin. As of November 2, she is Scientist at the GSC and an Assistant Professor in the Department of Medical Genetics at the University of British Columbia. Dr. Evgin’s research is focused on Chimeric antigen receptor (CAR) modified T cells and oncolytic viruses.
Oct 15, 2020

A deep learning-based approach for colorectal cancer diagnostics

Significant advancements in sequencing technologies have enabled rapid genomic and molecular characterization of cancers, improving diagnostics and treatment planning. The annotation of tumour tissue samples prior to these analyses, however, still requires the time and expertise of a pathologist and represents a bottleneck in cancer genomics.
Back to top